Skip to content

Smart Technology Facilitated Patient-centered Venous Thromboembolism Management

Smart Technology Facilitated Patient-centered Venous Thromboembolism Management: A Multicenter Cohort Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06350344
Acronym
SmaVTE-COR
Enrollment
2353
Registered
2024-04-05
Start date
2024-11-01
Completion date
2027-10-31
Last updated
2024-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digital Health, Health Education, Venous Thromboembolism

Keywords

Venous Thromboembolism, Mobile Health, Prophylaxis, Health Education

Brief summary

Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention. The objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE.

Interventions

mVTEA will assist in the management of patients with high-risk of VTE during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.

Sponsors

Navy General Hospital, Beijing
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Inpatients ≥18 years of age at admission; * At high-risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients; * Signed informed consent.

Exclusion criteria

* Diagnosis of VTE at discharge; * Mental disorder or combination of other serious diseases leading to incapacity for independent living; * Inability to use smartphones, computer tablets and other smart devices; * Being pregnant or breastfeeding; * Have participated in similar trials or are undergoing other clinical trials.

Design outcomes

Primary

MeasureTime frameDescription
VTE-related composite eventAt 1-year follow-upThe primary outcome was the occurrence of VTE-related composite event at 1-year follow-up, which was defined as a composite of VTE, major bleeding, VTE-related hospitalization, and all-cause death.

Secondary

MeasureTime frameDescription
Generic quality of lifeAt 3, 12, and 24-month follow-upGeneric, non-disease-specific health-related quality of life (QoL) is assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire and its corresponding visual analogue scale at 3, 12, and 24-month follow-up. Briefly, the EQ-5D-5L generates an overall index that ranges from 0 (lowest generic QoL) to 1 (highest generic QoL) and is calculated based on country-specific reference value sets. The EQ-5D-5L health index was calculated with the value set for China. The EuroQol visual analogue scale ranges from 0 to 100, with higher scores indicating better health.
VTE eventsAt 3, 6, 12, and 24-month follow-upVTE events will be documented during the follow-up. VTE events are categorized into two groups: new-onset VTE, and hospital-acquired VTE (HA-VTE). VTE that occurred for the first time during the study period, including deep vein thrombosis (DVT) and pulmonary embolism (PE), is classified as new-onset VTE. HA-VTE is defined as any new-onset VTE that has occurred within 90 days of hospital discharge.
Major bleedingAt 3, 6, 12, and 24-month follow-upThe major bleeding events as defined by the International Society on Thrombosis and Hemostasis (ISTH) will be documented during the follow-up.
VTE-KAP questionnaire scoreAt 3, 12, and 24-month follow-upThe VTE-KAP questionnaire is a self-administered questionnaire that includes demographic characteristics, knowledge, attitude, and practice (KAP) of patients towards VTE prevention and treatment. The VTE-KAP questionnaire consists of a total of 53 questions with an overall score range of 41 to 283. The higher the score, the higher the level of knowledge, attitude, and practice. The VTE-KAP questionnaire scores of the patients regarding the prevention and treatment of VTE will be evaluated at 3, 12, and 24-month follow-up.
New-onset of atrial fibrillation or atrial flutterAt 3, 6, 12, and 24-month follow-upThe new-onset of atrial fibrillation or atrial flutter will be documented during the follow-up.
DeathAt 3, 6, 12, and 24-month follow-upDeath will be documented during the follow-up. It is categorized into all-cause death and PE-related death. All-cause death is defined as death that occurs during the study period, regardless of cause.PE-related death is defined as death that is unequivocally due to PE.
VTE-related hospitalizationAt 3, 6, 12, and 24-month follow-upHospitalization due to the new-onset DVT and/or PE will be documented during the follow-up.

Countries

China

Contacts

Primary ContactZHI-GENG JIN, Doctor
lwgjzg@163.com8615801402223

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026